You are here: Industry Insights > Sanofi

News List

EU approval for Regeneron and Sanofi’s rheumatoid arthritis drug europeanpharmaceuticalreview
May 07, 2019
The European Commission (EC) has granted marketing authorisation for Regeneron and Sanofi’s Kevzara (sarilumab) for the treatment of rheumatoid arthritis…
Sanofi’s dengue vaccine secures FDA approval pharmaceutical-technology
May 06, 2019
Sanofi has received approval from the US Food and Drug Administration (FDA) for Dengvaxia, a vaccine that is designed to prevent all four dengue disease serotypes.
Sanofi’s dengue vaccine secures FDA approval pharmaceutical-technology
May 05, 2019
Sanofi has received approval from the US Food and Drug Administration (FDA) for Dengvaxia, a vaccine that is designed to prevent all four dengue disease serotypes.
Zynquista approved in EU for certain patients with type I diabetes pharmatimes
April 29, 2019
Sanofi has announced that its joint SGLT1/SGLT2 inhibitor with Lexicon, Zynquista (sotagliflozin), has been approved in Europe for certain patients with type I diabetes.
Sanofi concludes option phase of rare disease alliance with Alnylam pharmaceutical-technology
April 23, 2019
Sanofi concludes option phase of rare disease alliance with Alnylam.
Sanofi to slash costs of certain insulin products in US pharmaceutical-technology
April 23, 2019
Sanofi to slash costs of certain insulin products in US
Alnylam and Sanofi close research phase of 2014's $700m RNAi rare disease partnership pharmafile
April 11, 2019
Alnylam and Sanofi have announced their intention to bring to an end the research and option phase of a $700 million partnership originally launched in 2014 to develop RNAi therapeutics for rare conditions.
Sanofi expands insulin savings programme in US, providing some patients access for $99 per month firstwordpharma
April 10, 2019
Sanofi announced Wednesday that under an expanded programme in the US……
Sanofi and Alnylam Amend Rare Disease Alliance contractpharma
April 09, 2019
Sanofi and Alnylam Amend Rare Disease Alliance
Sanofi plans sales layoffs—again—in primary care, diabetes fiercepharma
April 04, 2019
Sanofi has been hit hard by pricing pressure in diabetes, and now the drugmaker’s U.S. sales force is set for another round of job cuts.